New Evidence Update

PDF cover

The Institute for Clinical and Economic Review (ICER) published this Final New Evidence Update for alirocumab (Praluent®, Regeneron/Sanofi), an injectable PCSK9 inhibitor used for the treatment of high cholesterol in certain patient populations. This New Evidence Update is based on further analysis of results from the ODYSSEY Outcomes trial, which have now undergone peer review and were published in the New England Journal of Medicine on November 7, 2018.


View All Materials on this Topic or Go Back to View More Materials